Cerdulatinib

Unknown Manufacturer

Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).

Generate AI report

Overview

Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).

Technical identifiers

Chemical Formula: C₂₀H₂₇N₇O₃S
CAS Number: 1198300-79-6
UNII ID: D1LXQ45S1O

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Methods for treating lymphoma
US 11266645 B2Applicant: ALEXION PHARMA INCPriority: 2018
CN
US
3 publications
Cerdulatinib for the treatment of b-cell malignancies
US 12350269 B2Applicant: ALEXION PHARMA INCPriority: 2015
CN
US
2 publications
Cerdulatinib for treating myeloma
US 12150942 B2Applicant: ALEXION PHARMA INCPriority: 2015
CN
US
2 publications
PHARMACEUTICAL COMPOSITION, ORGAN PRESERVATION SOLUTION, AND USE THEREOF
WO 2025162212 A1Applicant: THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVPriority: 2024
CN
WO
2 publications
Cerdulatinib for treating hematological cancers
US 10736895 B2Applicant: PORTOLA PHARM INCPriority: 2016
US
2 publications
Solid forms of cerdulatinib
US 10865198 B2Applicant: PORTOLA PHARM INCPriority: 2019
US
2 publications
Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
CN 111818910 AApplicant: DERMAVANT SCIENCES GMBHPriority: 2018
CN
Synthesis of cerdulatinib
US 11339145 B2Applicant: ALEXION PHARMA INCPriority: 2020
US
CIRCULATING B CELL SUBPOPULATIONS IN INDOLENT B CELL LYMPHOMA
US 2023181581 A1Applicant: ALEXION PHARMA INCPriority: 2021
US

Drugs